Hostname: page-component-745bb68f8f-s22k5 Total loading time: 0 Render date: 2025-02-03T00:24:49.619Z Has data issue: false hasContentIssue false
  • English
  • Français

Clobazam as an Add-on Drug in the Treatment of Refractory Epilepsy of Childhood

Published online by Cambridge University Press:  18 September 2015

D.L. Keene ,
S. Whiting  and
P. Humphreys
D.L. Keene*
Affiliation:
Section of Neurology, Department of Pediatrics, Childrens Hospital of Eastern Ontario, Ottawa
S. Whiting
Affiliation:
Section of Neurology, Department of Pediatrics, Childrens Hospital of Eastern Ontario, Ottawa
P. Humphreys
Affiliation:
Section of Neurology, Department of Pediatrics, Childrens Hospital of Eastern Ontario, Ottawa
*
Section of Neurology, Department of Pediatrics, Childrens Hospital of Eastern Ontario, 401 Smyth Rd., Ottawa, Ontario, Canada K1H 8L1
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

We report the results of a double-blind cross-over study comparing clobazam and placebo in the treatment of refractory childhood epilepsy. Fifty-two percent of patients had greater than 50% reduction in their seizure frequency when taking the clobazam. During the placebo phase no patient recorded a greater than 50% reduction in seizure frequency. Sex, age, seizure type, intellect did not appear to differentiate clobazam responsive from nonresponsive patients. Only 2/21 patients had behavioral changes on the drug sufficiently severe to require the patient to drop out of the study prematurely. Drug interactions between clobazam and the other anticonvulsant medicines did not occur.

Résumé:

RÉSUMÉ:

Nous rapportons les résultats d'une étude à double-insu en chassé-croisé comparant le clobazam et un placebo dans le traitement de l'épilepsie réfractaire de l'enfance. Cinquante deux pourcent des patients ont eu une diminution de la fréquence des crises de plus de 50% sous clobazam. Pendant la phase placebo, aucun patient n'a eu une réduction de la fréquence des crises de plus de 50%. Le sexe, l'âge, le type de crises, le niveau intellectuel ne semblent pas distinguer les répondeurs des non-répondeurs au clobazam. Seulement 2 patients sur 21 ont eu des modifications du comportement assez sévères pour motiver une sortie d'étude anticipée. Il n'y a pas eu d'interaction médicamenteuse entre le clobazam et les autres médicaments anticonvulsivants.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 17 , Issue 3 , August 1990 , pp. 317 - 319
Copyright
Copyright © Canadian Neurological Sciences Federation 1990

References

REFERENCES

1. Gastaut, H and Low, M. Antiepileptic properties of clobazam, a 1,5 benzodiazepine in man. Epilepsia 1979; 20: 437–446.Google Scholar
2. Gastaut, H. The effects of benzodiazepines on chronic epilepsy in man (with particular reference to clobazam). In: Hindmarch, I, Stonier, PD, (editor). Clobazam International Congress and Symposium Series. London: Royal Society of Medicine 1981; 43: 141–446.Google Scholar
3. Farrell, K. Benzodiazepines in the treatment of children with epilepsy. Epilepsia 1986; 27(1): S45–52.Google Scholar
4. Koeppen, D. A review of clobazam studies in epilepsy. In: Hindmarch, I, Stonier, PD, Trimble, MR (editor). Clobazam: Human Psychopharmacology and Clinical Applications. International Congress and Symposium Series. London: Royal Society of Medicine 1985; 74: 159–165.Google Scholar
5. Guberman, H, Sherwin, A, Blaschuk, K. Add-on trial of clobazam in 36 intractable epileptic patients, with plasma level correlations. Can J Neurol Sci 1989; 248 45 (Abst).Google Scholar